An automated, high‐throughput method for targeted quantification of intact insulin and its therapeutic analogs in human serum or plasma coupling mass spectrometric immunoassay with high resolution and accurate mass detection (MSIA‐HR/AM)
Analytical study reveals an automated mass spectrometric immunoassay for intact insulin and analogs in human blood, suggesting robust utility in clinical and anti-doping settings.
Key Points
To develop an automated, high-throughput assay for the simultaneous extraction and targeted quantification of intact human insulin and its synthetic therapeutic analogs in human serum or plasma.
Coupled targeted immunoenrichment via mass spectrometric immunoassay (MSIA) with high-resolution and accurate-mass (HR/AM) liquid chromatography-mass spectrometry (LC-MS).
Designed a multiplexed, semi-automated extraction and detection workflow to measure intact endogenous insulin and synthetic sequence variants across the clinical concentration range in human serum and plasma.
Successfully established a sensitive, selective, and semi-automated platform capable of simultaneous multi-analyte quantification across clinical ranges without sample handling bias.
Demonstrated assay capability to detect novel insulin isoforms, allowing their direct incorporation into subsequent generations of targeted assays.